Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP46 | DOI: 10.1530/endoabs.81.EP46

ECE2022 Eposter Presentations Adrenal and Cardiovascular Endocrinology (131 abstracts)

Ovarian cyst in woman treated with mitotane, side effects not to be ignored

Mouna Mezoued , Bessaid Khadidja & Malha Azzouz


Bologhine Hospital, Endocrinology, Alger, Algeria.


Introduction: Mitotane is an adrenolytic drug that is used as an adjuvant to treat adrenocortical carcinoma, The side effects of lysodren are numerous, but some of them are less known. We report a case of ovarian cyst in a woman of childbearing age. It is a 26 years old patient treated with Lysodren® for a locoregional recurrence of an adrenal cacinoma stage II of the ENSAT. After 9 months of treatment, the patient presented an amenorrhea, with the appearance of a large ovarian cyst of 50 mm, detected on the follow-up CT scan, which initially led to the suggestion of a recurrence. At presentation, FSH, luteinizing hormone (LH), were within the normal range, The levels of marker CA-125, occasionally controlled, remained normal. The cyst spontaneously disappeared 6 months after having stopped the treatment, and the patient became spontaneously pregnant having an uncomplicated delivery 2 years later.

Conclusion: Therapeutic concentrations of mitotane could be associated with the presence of benign ovarian cysts and amenorrhea, up to 50% of women. It is of clinical importance to be aware of this unwanted effect of mitotane, because finding a growing ovarian mass induces anxiety and may conduce to a misdiagnosis of ACC progression.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.